OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time
August 03, 2023 07:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter...
AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti
July 24, 2023 08:00 ET
|
AUROBAC THERAPEUTICS
Lyon - France, July 24, 2023 (GLOBE NEWSWIRE) -- AUROBAC THERAPEUTICS WELCOMES TWO NEW INDEPENDENT MEMBERS TO ITS BOARD: MANOS PERROS, AS CHAIRMAN, AND MARCO TAGLIETTI Dr Manos Perros and Dr...
OpGen’s Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND
July 19, 2023 07:30 ET
|
OpGen, Inc.
All milestones successfully met, including antibiotic stewardship module, mobile and cloud-based data access as well as comprehensive next generation sequencing resultsTriggers additional milestone...
Veterinary Antimicrobial Susceptibility Testing Market Expected to Exceed USD 76.2 Bn by 2032: TMR Study
June 28, 2023 14:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, June 29, 2023 (GLOBE NEWSWIRE) -- The global veterinary antimicrobial susceptibility testing market was valued at US$ 37.6 Bn in 2021 and is projected to expand...
OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe
June 26, 2023 07:30 ET
|
OpGen, Inc.
Patent EP 3 332 028 B1 granted by the European Patent Office covers the identification and use of genomic variants for the diagnosis of antibiotic resistant bacteria.The opposition division of...
OpGen’s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments
June 22, 2023 07:30 ET
|
OpGen, Inc.
Following final assembly and successful testing, a batch of ten Unyvero A30 instrument systems has been receivedLatest C-Series Unyvero A30 instruments optimized for series production and clinical...
Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances demonstrating potent in vitro and in vivo antimicrobial activity against MDR and XDR Enterobacteriaceae, including carbapenem-resistant and colistin-resistant strains
June 07, 2023 01:15 ET
|
Spexis AG
ALLSCHWIL, Switzerland, June 06, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced the publication of...
Antibiotics Global Market Report 2023: Significant Growth Potential of Cell Wall and Protein Inhibitor Drugs Bodes Well for Sector
May 23, 2023 04:18 ET
|
Research and Markets
Dublin, May 23, 2023 (GLOBE NEWSWIRE) -- The "Antibiotics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global market for antibiotics was...
OpGen Reports First Quarter 2023 Financial Results and Provides Business Update
May 15, 2023 16:15 ET
|
OpGen, Inc.
Total revenue for the first quarter of 2023 was approximately $0.91 million, an increase of approximately 94% compared to the first quarter of 2022Expanded U.S. growth opportunities with the Unyvero...
World Antimicrobial Resistance Diagnostic Market Research Report 2023-2027: From Multiple Pathogens to All Pathogens - The Next Next Generation
April 18, 2023 03:53 ET
|
Research and Markets
Dublin, April 18, 2023 (GLOBE NEWSWIRE) -- The "Antimicrobial Resistance Diagnostic Markets, Strategies and Trends by Pathogen and Technology, With Executive Guides and Customization 2023 to 2027"...